bluebird bio’s Zynteglo (betibeglogene autotemcel) Receives the US FDA’s Approval for the Treatment of Beta-Thalassemia
Shots:
- The US FDA has approved Zynteglo (ex-vivo LVV gene therapy) to treat beta‑thalassemia in adult & pediatric patients who required regular RBC transfusions
- The approval was based on the P-III (Northstar-2 & 3) & the long-term follow-up (LTF-303) study to evaluate Zynteglo in 41 patients aged 4 to 34yrs. with beta‑thalassemia with non-β0/β0 & β0/β0 genotypes. The results showed that 89% of patients achieved durable transfusion independence (TI) & remained transfusion-free for 12mos. along with normal or near normal total Hb levels
- The company is also conducting a long-term follow-up (LTF-303) study to monitor the safety & effectiveness of LVV gene therapy for TDT patients who have participated in sponsored clinical studies for 15yrs. post-treatment
Ref: Businesswire | Image: bluebird bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
